is bpc-157 banned by wada 2024 Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review ⚠️Peptides and synthetic peptides are

Sticking to recommended doses is key to minimizing potential risks and achieving optimal benefits

Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population

Although the drugs are still pricey, the costs for some brands have dropped significantly since they were first introduced, says Wood

Retatrutide drives the deep metabolic effect, including the glucagon-mediated bump in energy expenditure that sets it apart from older incretin drugs

Glucagon, the hormone that raises blood sugar, gets suppressed